Zydus Lifesciences Ltd

The investor presentation for Zydus Lifesciences Limited's Q2 FY27, dated November 4, 2026, outlines the company's financial and operational performance. Total revenues from operations grew 29% YoY to Rs. 79,096 million, driven by strong performance across India, North America, and International Markets formulations businesses. India's branded formulations outperformed the market with 19% YoY growth, supported by chronic portfolio expansion and new product launches. North America's formulations business saw growth from sustained volume expansion and specialty portfolio momentum, including the launch of a generic Riociguat tablet. International Markets reported broad-based growth, with a focused therapy approach in emerging markets and portfolio expansion in Europe. Consumer Wellness delivered 29% YoY growth in India, with strong performance in skin and hair care and food nutrition segments. EBITDA margin stood at 24.0%, while capex was Rs. 4,655 million. The company also highlighted regulatory approvals, including USFDA inspections and a transdermal product approval. R&D investment amounted to Rs. 6,573 million, or 8.3% of revenues. The presentation included forward-looking statements about future growth and strategies, noting risks and uncertainties associated with such projections. The company's ESG rating improved to 71/100, placing it in the 'Leader' category. Net profit for the quarter was Rs. 9,255 million, reflecting a 26.6% decline YoY, partly due to exchange rate fluctuations and higher operating expenses.

The presentation highlights both strong revenue growth and significant declines in net profit, reflecting a balanced mix of positive and negative elements.